Treatment with γ-tocotrienol (2 μM), the PPARγ agonist, rosiglitazone (3.2 μM), and the PPARγ antagonist, GW9662 (3.2 μM) alone had no significant effect on PGD2 synthesis in +SA breast cancer cells compared to vehicle-treated control cells. This evidence concerns the gene PPARG and breast cancer.